Join
Live feed
·
PRReleasevia Quantisnow
Definium Therapeutics Inc. logo

Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder

ByQuantisnow·Wall Street's wire, on your screen.
DFTX· Definium Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DFTX (Definium Therapeutics Inc.) and more on Quantisnow.